Spero Therapeutics (SPRO) EBIT (QoQ) (2016 - 2026)
Spero Therapeutics (SPRO) EBIT (QoQ) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Spero Therapeutics | 71.59 Mn | 20.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.68% |
| Mar 31, 2026 | -125.76% |
| Dec 31, 2025 | 496.40% |
| Sep 30, 2025 | -202.05% |
| Jun 30, 2025 | 83.41% |
| Mar 31, 2025 | 32.19% |
| Dec 31, 2024 | -24.59% |
| Sep 30, 2024 | 8.52% |
| Jun 30, 2024 | -36.33% |
| Mar 31, 2024 | -129.34% |
| Dec 31, 2023 | 2,564.06% |
| Sep 30, 2023 | 85.00% |
| Jun 30, 2023 | 9.40% |
| Mar 31, 2023 | -165.54% |
| Dec 31, 2022 | 283.42% |
| Sep 30, 2022 | 54.62% |
| Jun 30, 2022 | 13.66% |
| Mar 31, 2022 | -9.84% |
| Dec 31, 2021 | -22.10% |
| Sep 30, 2021 | -21.48% |